India Pharma - IPM Growth Normalised In July With Fall In Covid-19 Cases: Prabhudas Lilladher
India Pharma - IPM Growth Normalised In July With Fall In Covid-19 Cases: Prabhudas Lilladher
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Prabhudas Lilladher Report
Increased pace of vaccination and slowing of wave-two of Covid-19 led to normalised Indian pharma market growth month-on-month.
Growth maintained the momentum in July 2021 with strong contribution from high growth therapies influenced by Covid-19 products.
The key reasons for such growth are:
increased percentage of vaccinated population with more players entering into Covid-19 vaccine segment,
ease in travel restriction and less likelihood of another lock-down,
precautionary Covid-19 products continued its market share with increased demand on opening of economy and
falling incidence of Covid-19 increased demand for other therapies.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.